Wire · regulatory
AI Antibody Design Just Got Its First Honest Report Card — And the Grade Is Complicated
◆ Sectors
◆ Source
◆ Verified
Fusion42 · 21 August 2026 · Fusion42 review
A blinded prospective benchmark of AI-driven antibody design reveals wide performance variation with no consensus best method, exposing a Validation Gap in evidentiary standards for AI in drug development. Regulatory guidance lacks operational specifics for AI tool validation in submissions, creating uncertainty for sponsors relying on computational candidates.
This Wire brief sits within Fusion42's coverage of Biotech, AI Frontier Models and Drug Discovery.
◆ ◆ The Wire takeaway
AI drug discovery founders face fresh regulatory uncertainty as guidelines lack clarity on acceptable validation for AI-designed antibodies. You need to build rigorous, auditable evidence now or risk delays when seeking approval.
◆ Coverage
1 source · 21 Aug 2026
◆ Related on Wire
◆ Topics